This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Keshelava, N. Articles by Reynolds, C. P. Search for Related Content PubMed PubMed Citation Articles by Keshelava, N. Articles by Reynolds, C. P.

Drug Resistance Patterns of Human Neuroblastoma Cell Lines Derived from Patients at Different Phases of Therapy¹

Division of Hematology-Oncology, Childrens Hospital Los Angeles, Los Angeles, California 90033 [N. K., R. C. S., C. P. R.], and Departments of Pediatrics [N. K., R. C. S., C. P. R.], Pathology [C. P. R.], and Preventive Medicine [S. G.], University of Southern California School of Medicine, Los Angeles, California

To determine whether neuroblastomas acquire a sustained drug-resistant phenotype from exposure to chemotherapeutic agents given to patients in vivo, we studied neuroblastoma cell lines established at different points of therapy: six at diagnosis before therapy (DX), six at progressive disease during induction therapy (PD-Ind), and five at relapse after intensive chemoradiotherapy and bone marrow transplantation (PD-BMT). Cells were maintained in the absence of drug selective pressure. Dose-response curves of melphalan, cisplatin, carboplatin, doxorubicin, and etoposide for the cell line panel were determined by measuring cytotoxicity with a 96-well-plate digital imaging microscopy (DIMSCAN) microassay. Drug resistance of cell lines progressively increased with the intensity of therapy delivered in vivo. The greatest resistance was seen in PD-BMT cell lines: IC₉₀ values in PD-BMT cell lines were higher than clinically achievable drug levels by 1–37 times for melphalan, 1–9 times for carboplatin, 25–78 times for cisplatin, 6–719 times for doxorubicin, and 3–52 times for etoposide. Genomic amplification of MYCN did not correlate with resistance. Cross-resistance by Pearson correlation (r 0.6) was observed between: (a) cisplatin + doxorubicin; (b) carboplatin + cisplatin, etoposide, or melphalan; (c) etoposide + cisplatin, melphalan, or doxorubicin. These data indicate that during therapy, neuroblastomas can acquire resistance to cytotoxic drugs because of the population expansion of tumor cells possessing stable genetic or epigenetic alterations that confer resistance.

¹ Supported in part by a Childrens Hospital Los Angeles Research Institute Research Career Development Fellowship; the Neil Bogart Memorial Laboratories of the T. J. Martell Foundation for Leukemia, Cancer, and AIDS Research; by National Cancer Institute Grants CA60104, CA13539, and CA14089; and by the American Institute for Cancer Research.

² To whom requests for reprints should be addressed, at Division of Hematology-Oncology, MS# 57, Childrens Hospital Los Angeles, 4650 Sunset Boulevard, Los Angeles, CA 90027. Phone: (323) 669-5646; Fax: (323) 664-9226/9455; E-mail: cpreynol@hsc.usc.edu.

Received 2/27/98. Accepted 9/25/98.

This article has been cited by other articles:

				X. Qi, Z. Chu, Y. Y. Mahller, K. F. Stringer, D. P. Witte, and T. P. Cripe Cancer-Selective Targeting and Cytotoxicity by Liposomal-Coupled Lysosomal Saposin C Protein Clin. Cancer Res., September 15, 2009; 15(18): 5840 - 5851. [Abstract] [Full Text] [PDF]

				T. M. Harned, O. Kalous, A. Neuwelt, J. Loera, L. Ji, P. Iovine, R. Sposto, E. A. Neuwelt, and C. P. Reynolds Sodium Thiosulfate Administered Six Hours after Cisplatin Does Not Compromise Antineuroblastoma Activity Clin. Cancer Res., January 15, 2008; 14(2): 533 - 540. [Abstract] [Full Text] [PDF]

				B. Gesundheit, A. Moser, R. Or, and G. Klement Successful Antiangiogenic Therapy for Neuroblastoma With Thalidomide J. Clin. Oncol., November 20, 2007; 25(33): 5321 - 5324. [Full Text] [PDF]

				N. Keshelava, E. Davicioni, Z. Wan, L. Ji, R. Sposto, T. J. Triche, and C. P. Reynolds Histone Deacetylase 1 Gene Expression and Sensitization of Multidrug-Resistant Neuroblastoma Cell Lines to Cytotoxic Agents by Depsipeptide J Natl Cancer Inst, July 18, 2007; 99(14): 1107 - 1119. [Abstract] [Full Text] [PDF]

				B. J. Maurer, O. Kalous, D. W. Yesair, X. Wu, J. Janeba, V. Maldonado, V. Khankaldyyan, T. Frgala, B.-C. Sun, R. T. McKee, et al. Improved Oral Delivery of N-(4-Hydroxyphenyl)Retinamide with a Novel LYM-X-SORB Organized Lipid Complex Clin. Cancer Res., May 15, 2007; 13(10): 3079 - 3086. [Abstract] [Full Text] [PDF]

				T. Frgala, O. Kalous, R. T. Proffitt, and C. P. Reynolds A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations Mol. Cancer Ther., March 1, 2007; 6(3): 886 - 897. [Abstract] [Full Text] [PDF]

				J. Karlsson, A. Edsjo, S. Pahlman, and H. M. Pettersson Multidrug-resistant neuroblastoma cells are responsive to arsenic trioxide at both normoxia and hypoxia Mol. Cancer Ther., July 1, 2005; 4(7): 1128 - 1135. [Abstract] [Full Text] [PDF]

				B. Yang and C. P. Reynolds Tirapazamine Cytotoxicity for Neuroblastoma Is p53 Dependent Clin. Cancer Res., April 1, 2005; 11(7): 2774 - 2780. [Abstract] [Full Text] [PDF]

				R. Torkin, J.-F. Lavoie, D. R. Kaplan, and H. Yeger Induction of caspase-dependent, p53-mediated apoptosis by apigenin in human neuroblastoma Mol. Cancer Ther., January 1, 2005; 4(1): 1 - 11. [Abstract] [Full Text] [PDF]

				S. Batra, C. P. Reynolds, and B. J. Maurer Fenretinide Cytotoxicity for Ewing's Sarcoma and Primitive Neuroectodermal Tumor Cell Lines Is Decreased by Hypoxia and Synergistically Enhanced by Ceramide Modulators Cancer Res., August 1, 2004; 64(15): 5415 - 5424. [Abstract] [Full Text] [PDF]

				J. Karlsson, I. Ora, I. Porn-Ares, and S. Pahlman Arsenic Trioxide-Induced Death of Neuroblastoma Cells Involves Activation of Bax and Does Not Require p53 Clin. Cancer Res., May 1, 2004; 10(9): 3179 - 3188. [Abstract] [Full Text] [PDF]

				H. Goto, B. Yang, D. Petersen, K. A. Pepper, P. A. Alfaro, D. B. Kohn, and C. P. Reynolds Transduction of green fluorescent protein increased oxidative stress and enhanced sensitivity to cytotoxic drugs in neuroblastoma cell lines Mol. Cancer Ther., September 1, 2003; 2(9): 911 - 917. [Abstract] [Full Text] [PDF]

				N. Keshelava, D. Tsao-Wei, and C. P. Reynolds Pyrazoloacridine Is Active in Multidrug-resistant Neuroblastoma Cell Lines with Nonfunctional p53 Clin. Cancer Res., August 1, 2003; 9(9): 3492 - 3502. [Abstract] [Full Text] [PDF]

				B. Yang, N. Keshelava, C. P. Anderson, and C. P. Reynolds Antagonism of Buthionine Sulfoximine Cytotoxicity for Human Neuroblastoma Cell Lines by Hypoxia Is Reversed by the Bioreductive Agent Tirapazamine Cancer Res., April 1, 2003; 63(7): 1520 - 1526. [Abstract] [Full Text] [PDF]

				P. J. Houghton, P. C. Adamson, S. Blaney, H. A. Fine, R. Gorlick, M. Haber, L. Helman, S. Hirschfeld, M. G. Hollingshead, M. A. Israel, et al. Testing of New Agents in Childhood Cancer Preclinical Models: Meeting Summary Clin. Cancer Res., December 1, 2002; 8(12): 3646 - 3657. [Abstract] [Full Text] [PDF]

				L. S. Metelitsa, O. V. Naidenko, A. Kant, H.-W. Wu, M. J. Loza, B. Perussia, M. Kronenberg, and R. C. Seeger Human NKT Cells Mediate Antitumor Cytotoxicity Directly by Recognizing Target Cell CD1d with Bound Ligand or Indirectly by Producing IL-2 to Activate NK Cells J. Immunol., September 15, 2001; 167(6): 3114 - 3122. [Abstract] [Full Text] [PDF]

				N. Keshelava, J. J. Zuo, P. Chen, S. N. Waidyaratne, M. C. Luna, C. J. Gomer, T. J. Triche, and C. P. Reynolds Loss of p53 Function Confers High-Level Multidrug Resistance in Neuroblastoma Cell Lines Cancer Res., August 1, 2001; 61(16): 6185 - 6193. [Abstract] [Full Text] [PDF]

				D. S. B. Hoon, C. T. Kuo, S. Wen, H. Wang, L. Metelitsa, C. P. Reynolds, and R. C. Seeger Ganglioside GM2/GD2 Synthetase mRNA Is a Marker for Detection of Infrequent Neuroblastoma Cells in Bone Marrow Am. J. Pathol., August 1, 2001; 159(2): 493 - 500. [Abstract] [Full Text]

				H. Wang, B. J. Maurer, C. P. Reynolds, and M. C. Cabot N-(4-Hydroxyphenyl)retinamide Elevates Ceramide in Neuroblastoma Cell Lines by Coordinate Activation of Serine Palmitoyltransferase and Ceramide Synthase Cancer Res., July 1, 2001; 61(13): 5102 - 5105. [Abstract] [Full Text] [PDF]

				N. D. Doolittle, C. P. Anderson, W. A. Bleyer, J. G. Cairncross, T. Cloughesy, S. L. Eck, P. Guastadisegni, W. A. Hall, L. L. Muldoon, S. J. Patel, et al. Importance of dose intensity in neurooncology clinical trials: Summary Report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium Neuro-oncol, January 1, 2001; 3(1): 46 - 54. [Abstract] [PDF]

				D. A. Tweddle, A. J. Malcolm, N. Bown, A. D. J. Pearson, and J. Lunec Evidence for the Development of p53 Mutations after Cytotoxic Therapy in a Neuroblastoma Cell Line Cancer Res., January 1, 2001; 61(1): 8 - 13. [Abstract] [Full Text]

				P. M. Thompson, J. M. Maris, M. D. Hogarty, R. C. Seeger, C. P. Reynolds, G. M. Brodeur, and P. S. White Homozygous Deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at Other Tumor Suppressor Loci in Neuroblastoma Cancer Res., January 1, 2001; 61(2): 679 - 686. [Abstract] [Full Text]

				B. J. Maurer, L. Melton, C. Billups, M. C. Cabot, and C. P. Reynolds Synergistic Cytotoxicity in Solid Tumor Cell Lines Between N-(4-Hydroxyphenyl)retinamide and Modulators of Ceramide Metabolism J Natl Cancer Inst, December 6, 2000; 92(23): 1897 - 1909. [Abstract] [Full Text] [PDF]

				B. J. Maurer, L. S. Metelitsa, R. C. Seeger, M. C. Cabot, and C. P. Reynolds Increase of Ceramide and Induction of Mixed Apoptosis/Necrosis by N-(4-Hydroxyphenyl)- retinamide in Neuroblastoma Cell Lines J Natl Cancer Inst, July 7, 1999; 91(13): 1138 - 1146. [Abstract] [Full Text] [PDF]

				X. F. Hu, A. Slater, P. Kantharidis, D. Rischin, S. Juneja, R. Rossi, G. Lee, J. D. Parkin, and J. R. Zalcberg Altered Multidrug Resistance Phenotype Caused by Anthracycline Analogues and Cytosine Arabinoside in Myeloid Leukemia Blood, June 15, 1999; 93(12): 4086 - 4095. [Abstract] [Full Text] [PDF]